ANDAs Must Include All Bioequivalence Data: FDA

Law360, New York (January 20, 2009, 12:00 AM EST) -- The U.S. Food and Drug Administration issued a final rule Tuesday requiring pharmaceutical companies that apply to sell generic medications to provide data from all the bioequivalence studies they conduct on a proposed drug, regardless of whether it supports their application or not.

Until now, abbreviated new drug applications have only had to include bioequivalence studies showing that a generic product meets the FDA's bioequivalence standards. Applicants have not had to hand over studies that, for instance, do not prove that the product satisfies the criteria,...
To view the full article, register now.